Gilenya vs. Baclofen: side effect and effectiveness comparison (a real world drug study)
Summary:
We compare the side effects and drug effectiveness of Gilenya and Baclofen. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 239,707 people who take Gilenya and Baclofen, and is updated regularly.
What is Gilenya?
Gilenya has active ingredients of fingolimod. It is often used in multiple sclerosis. eHealthMe is studying from 111,893 Gilenya users. Check the latest studies of Gilenya.
What is Baclofen?
Baclofen has active ingredients of baclofen. It is often used in muscle spasms. eHealthMe is studying from 108,662 Baclofen users. Check the latest studies of Baclofen.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
239,707 people who take Gilenya and Baclofen are studied.
Drugs being compared in this study:
- Gilenya (fingolimod)
- Baclofen (baclofen)
Most common side effects of the drugs, overall:
Most common side effects of the drugs, in long term (1+ years) use:
Drug effectiveness:
Gilenya:
- not at all: 2.74 %
- somewhat: 16.89 %
- moderate: 43.38 %
- high: 26.48 %
- very high: 10.5 %
Baclofen:
- not at all: 5.57 %
- somewhat: 28.34 %
- moderate: 35.77 %
- high: 19.31 %
- very high: 11.02 %
Want to compare Gilenya with Baclofen?
- Personalize this study to your gender and age (0-99+)How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Related studies
Alternative drugs to, pros and cons of:
Browse all side effects of Gilenya:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Baclofen:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study is based on fingolimod and baclofen (the active ingredients of Gilenya and Baclofen, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Doxycycline cause Physical Disability? - 7 seconds ago
- Drug interactions of Otezla and Diazepam - 8 seconds ago
- Multiple Myeloma and Lung Cancer - Small Cell - 9 seconds ago
- Could Olanzapine cause Posterior Reversible Encephalopathy Syndrome? - 10 seconds ago
- Gazyva and Acyclovir drug interactions for men aged 60+ - 14 seconds ago
- Could Amlodipine cause Chronic Kidney Disease? - 16 seconds ago
- Could Sertraline Hydrochloride cause Protein Urine Present? - 17 seconds ago
- Could Lactobacillus cause Dry Mouth? - 18 seconds ago
- Could Crestor cause Infection? - 19 seconds ago
- Hc and Aspirin drug interactions for men aged 60+ - 23 seconds ago